Ortin Laboratories

Hyderabad, India Founded: 1986 • Age: 40 yrs Listed
Entertainment talent is connected to projects through a digital platform.

About Ortin Laboratories

Ortin Laboratories is a publicly listed company based in Hyderabad (India) founded in 1986. Entertainment talent is connected to projects through a digital platform. It operates on a Reseller / Distribution and B2B2C model. Its chief executive, as recorded, is Murali Krishna Murthy Sanka. Its Indian entity Ortin Global Limited reported revenue of β‚Ή41 Lakh. Ortin Laboratories offers products and services including Formulations, API, Intermediates, and Bio-technology. Its focus areas include Pharmaceuticals and Drug Manufacturing.

Company details

Ortin Laboratories Limited is involved in the development and manufacturing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and chemical intermediates. The company is also active in biotechnology solutions and merchant export trading. Operations are focused on the healthcare sector, providing products for medical and research applications. Additionally, export and import business opportunities are pursued to expand global presence. The company is based in Hyderabad, India, and serves various clients worldwide.

  • Headquarters Hyderabad, India
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website ortinlabsindia.com
  • Legal Name Ortin Global Ltd
Key Metrics
  • Market Cap
    ₹10.51 Cr

    ORTINGLOBE · NSE

  • Share Price
    ₹12.50

    -3.33% today

  • Revenue
    ₹0.41 Cr

    FY 2025-26 · +20.6% YoY

  • EBITDA
    −₹0.73 Cr

    Margin -178.1%

  • Net Profit
    −₹0.75 Cr

    FY 2025-26 · +12.8% YoY

  • P/E (TTM)
    15.4x

    P/B 1.2x

  • Debt / Equity
    0.39

    Interest cover 0.0x

Products & Services of Ortin Laboratories

Ortin Laboratories offers a comprehensive portfolio of products and services, including Formulations, API, Intermediates, and Bio-technology.

Formulations
Pharmaceuticals

Pharmaceutical formulations are developed for various medical applications.

API
Pharmaceuticals

Active pharmaceutical ingredients are produced for drug manufacturing.

Intermediates
Pharmaceuticals

Chemical intermediates are manufactured for pharmaceutical production processes.

Bio-technology
Biotech

Biotechnology solutions are offered for healthcare and research.

Board of directors of Ortin Global Limited (Ortin Laboratories)

Ortin Global Limited is the primary company behind Ortin Laboratories. The boards of the 2 registered companies of Ortin Laboratories currently have 9 directors; the longest-serving is Gaddam Venkata Ramana, appointed in 2015. 46 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Gaddam Venkata Ramana
DIN 00031873
Director27 Apr 201511 yrs 6 moVineet Chem Trade Private Limited
Murali Krishna Murthy Sanka
DIN 00540632
Nodal Officer03 Sep 20197 yrs 2 moOrtin Global Limited
Venkptarama Gaddam
DIN 02696624
Director15 Jun 20224 yrs 5 moVineet Chem Trade Private Limited
Pramod Dnyandeo Waghe
DIN 10506276
Director13 Feb 20242 yrs 9 moOrtin Global Limited
Mounika Pammi
DIN 11111376
Director26 May 20251 yr 5 moOrtin Global Limited
Sarang Balbhimrao Patodekar
DIN 08501875
Director10 Jul 20251 yr 4 moOrtin Global Limited
Prashant Prakash Sawant
DIN 11128335
Whole-time director10 Jul 20251 yr 4 moOrtin Global Limited
Ajay Vishwakarma
DIN 11163644
Director10 Jul 20251 yr 4 moOrtin Global Limited
Prakruti Prashant Sawant
DIN 11162997
Whole-Time Director10 Jul 20251 yr 4 moOrtin Global Limited

People of Ortin Laboratories

1 people are tracked at Ortin Laboratories (1 in leadership).

NameRoleGroup
CEO & Managing DirectorLeadership
Premium access

Complete people profiles for Ortin Laboratories

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Ortin Laboratories

Ortin Laboratories is a publicly listed company on the NSE with ticker symbol ORTINGLOBE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date30 Mar 2021
  • Listed onNSE: ORTINGLOBE
  • Listed entityOrtin Global Ltd
  • Exchange sectorHealth technology
  • ISININE749B01020
  • Share price₹15.19 (-0.59% on the day) · 2026-10-14
  • Market capitalisation₹12.1 Cr
  • EPS (diluted, trailing year)₹-1.11
  • Volume (last session)1,000

Financials of Ortin Laboratories

Exchange-reported figures of Ortin Global Limited, the listed company behind Ortin Laboratories (NSE: ORTINGLOBE).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹0.41 Cr
+20.6% YoY
EBITDA
−₹0.73 Cr
+17.0% YoY
Profit After Tax
−₹0.75 Cr
+12.8% YoY
Net Worth
₹1.24 Cr
-37.4% YoY
Total Assets
₹2.24 Cr
+0.4% YoY
Total Debt
₹1.01 Cr
+304.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.410.342.116.028.238.17197
Revenue growth+20.6%-83.9%-65.0%-26.9%+0.7%-95.9%-
EBITDA(0.73)(0.88)(6.54)0.500.361.255.69
EBITDA margin-178.1%-258.8%-310.0%+8.3%+4.4%+15.3%+2.9%
Profit before tax(0.73)(0.83)(7.08)(0.11)(0.55)0.140.71
Net profit(0.75)(0.86)(6.28)(0.07)(0.42)0.95(0.57)
Net profit margin-182.9%-252.9%-297.6%-1.2%-5.1%+11.6%-0.3%
EPS (β‚Ή)(0.91)(1.04)(9.89)(0.12)(0.49)1.16(0.33)
Balance sheet
Total assets2.242.234.6317.4517.2418.4844.82
Net worth1.241.982.8210.8610.9611.3523.82
Total debt1.010.251.806.456.146.9419.57
Cash & bank0.610.372.340.260.600.182.50
Net working capital1.431.784.313.042.563.7323.25
Cash flow
Cash from operations(0.56)(0.41)(4.79)(0.25)2.1518.033.30
Cash from investing0.040.0012.000.01(0.13)0.07(3.09)
Cash from financing0.750.33(3.49)0.90(0.48)(9.86)(1.33)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.040.010.300.010.010.080.090.03
Revenue growth (YoY)+300.0%-87.5%+233.3%-66.7%-80.0%-61.9%--
Other income0.000.000.000.000.000.000.000.02
Total expenses0.310.350.320.060.520.240.250.17
EBITDA(0.27)(0.34)(0.02)(0.05)(0.51)(0.16)(0.16)(0.14)
EBITDA margin-900.0%-3400.0%-66.7%-500.0%-5100.0%-400.0%-320.0%-466.7%
Depreciation0.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.00(0.01)
Profit before tax(0.27)(0.34)(0.02)(0.05)(0.51)(0.16)(0.16)(0.11)
Tax0.000.000.000.000.000.010.000.01

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 16 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.040.010.300.010.010.080.090.03
Revenue growth (YoY)+300.0%-87.5%+233.3%-66.7%-80.0%-61.9%--
Other income0.000.000.000.000.000.000.000.02
Total expenses0.310.350.320.060.520.240.250.17
EBITDA(0.27)(0.34)(0.02)(0.05)(0.51)(0.16)(0.16)(0.14)
EBITDA margin-900.0%-3400.0%-66.7%-500.0%-5100.0%-400.0%-320.0%-466.7%
Depreciation0.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.00(0.01)
Profit before tax(0.27)(0.34)(0.02)(0.05)(0.51)(0.16)(0.16)(0.11)
Tax0.000.000.000.000.000.010.000.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.410.342.116.028.238.17197
Revenue growth+20.6%-83.9%-65.0%-26.9%+0.7%-95.9%-
Other income0.000.060.170.040.190.050.19
Total expenses1.141.228.655.527.876.92192
Employee cost0.000.090.490.680.740.854.72
EBITDA(0.73)(0.88)(6.54)0.500.361.255.69
EBITDA margin-178.1%-258.8%-310.0%+8.3%+4.4%+15.3%+2.9%
Depreciation0.000.010.230.250.290.291.96
Interest0.000.000.480.400.810.873.21
Profit before tax(0.73)(0.83)(7.08)(0.11)(0.55)0.140.71
Tax0.020.010.96(0.02)(0.13)(0.81)1.29
Net profit(0.75)(0.86)(6.28)(0.07)(0.42)0.95(0.57)
Net profit margin-182.9%-252.9%-297.6%-1.2%-5.1%+11.6%-0.3%
EPS (β‚Ή)(0.91)(1.04)(9.89)(0.12)(0.49)1.16(0.33)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital8.138.138.138.138.138.1316.94
Reserves & surplus(6.89)(6.15)(5.31)2.732.833.226.88
Shareholders' funds (net worth)1.241.982.8210.8610.9611.3523.82
Secured loans0.000.000.003.493.485.912.71
Unsecured loans1.010.251.802.962.661.0316.86
Total debt1.010.251.806.456.146.9419.57
Total liabilities2.242.234.6317.4517.2418.4844.82
Assets
Gross block0.010.000.2118.7819.0418.9129.44
Net block0.010.000.0113.9614.2114.3722.45
Capital work in progress0.000.000.000.430.430.430.43
Investments0.000.000.000.000.000.000.07
Inventories0.000.020.052.601.741.8349.90
Sundry debtors0.200.261.773.423.243.9137.15
Cash & bank balances0.610.372.340.260.600.182.50
Loans & advances3.032.682.190.260.180.202.86
Total current assets3.843.336.356.545.766.1292.41
Total current liabilities2.411.552.043.503.202.3969.16
Net working capital1.431.784.313.042.563.7323.25
Total assets2.242.234.6317.4517.2418.4844.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.370.46(3.26)(3.92)(5.47)(13.72)(12.60)
Net cash from operating activities(0.56)(0.41)(4.79)(0.25)2.1518.033.30
Net cash from investing activities0.040.0012.000.01(0.13)0.07(3.09)
Net cash from financing activities0.750.33(3.49)0.90(0.48)(9.86)(1.33)
Net change in cash0.23(0.09)3.720.661.558.25(1.12)
Closing cash0.610.372.340.260.600.182.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+20.6%-83.9%-65.0%-26.9%+0.7%-95.9%-
EBITDA growth+17.1%+86.5%-1408.0%+38.9%-71.2%-78.0%-
PBT growth+13.3%+88.3%-6336.4%+80.0%--80.3%-61.4%
Net income growth+12.8%+86.3%-8871.4%+83.3%-144.2%+266.7%-
Revenue CAGR (3Y)-74.5%-65.4%-36.3%-68.8%-63.4%-53.2%+47.2%
EBITDA CAGR (3Y)----55.5%-62.2%-38.6%+1.5%
Profitability & leverage
Net income margin-740.0%-247.1%-381.0%-1.5%-5.1%+11.6%-0.3%
Return on capital employed0.0%0.0%0.0%+1.8%+1.6%+3.2%+8.7%
Return on net worth0.0%0.0%0.0%-0.6%-3.6%+5.4%-2.3%
Debt / equity0.390.430.600.580.590.750.80
Long-term debt / equity0.390.430.35-15,854.61-15,506.460.180.20
Interest cover0.000.00-7.09160.001,157.1490.6386.06
Efficiency & per share
Fixed asset turnover20.003.240.220.320.430.347.08
Inventory turnover10.009.711.592.774.610.324.55
Debtors turnover0.430.330.811.812.300.405.27
EPS (β‚Ή)(0.91)(1.04)(9.89)(0.12)(0.49)1.16(0.33)
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)1.522.433.4713.3613.4713.9714.06

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Ortin Laboratories (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ortin Laboratories

Premium access

Complete news archive for Ortin Laboratories

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ortin Laboratories

Ortin Laboratories was founded in 1986.

Ortin Laboratories is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Murali Krishna Murthy Sanka is the CEO of Ortin Laboratories, as recorded in our data.

The primary company behind Ortin Laboratories, Ortin Global Limited, reported revenue of β‚Ή41 Lakh for FY 2026, up 21% year on year.

Ortin Laboratories Limited is involved in the development and manufacturing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and chemical intermediates. The company is also active in biotechnology solutions and merchant export trading. Operations are focused on the healthcare sector, providing products for medical and research applications. Additionally, export and import business opportunities are pursued to expand global presence. The company is based in Hyderabad, India, and serves various clients worldwide.

Ortin Laboratories offers Formulations, API, Intermediates, and Bio-technology.

Yes, Ortin Laboratories is publicly traded on NSE under the ticker symbol ORTINGLOBE.

Ortin Laboratories is associated with 2 legal entities: Ortin Global Limited, Vineet Chem Trade Private Limited.

The legal entities of Ortin Laboratories currently have 11 directors, including Gaddam Venkata Ramana, Venkptarama Gaddam, Sarang Balbhimrao Patodekar and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available